Research at RIKEN has led to the identification of furanocoumarin derivatives acting as dihydroorotate dehydrogenase (DHODH) inhibitors reported to be useful for the treatment of cancer and viral infections.

Phosphatidylinositol 3-kinase α (PI3Kα) inhibitors have been reported in a Synnovation Therapeutics Inc. patent as useful for the treatment of cancer, PIK3CA-related overgrowth spectrum, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities.

Orexia Therapeutics Ltd. has identified bicyclic-heterocycle derivatives acting as orexin OX2 receptor agonists. As such, they are reported to be useful for the treatment of narcolepsy, circadian rhythm disorder, genetic disorders, coma, metabolic syndrome, neurodegeneration, osteoporosis and sleep apnea, among others.

Research at Kinnate Biopharma Inc. has led to the development of mitogen-activated protein kinase kinase (MAP2K; MEK; MAPKK) inhibitors reported to be useful for the treatment of cancer.

Aromatic ring-substituted methoxy derivatives have been described in a Shanghai Yingli Pharmaceutical Co. Ltd. patent as potentially useful for the treatment of liver and stomach cancer.

Gilead Sciences Inc. researchers have identified new nucleoside analogues reported to be useful for the treatment of viral infection.

Denali Therapeutics Inc. has patented new NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors reported to be useful for the treatment of glaucoma, spinal cord Injury, leukoencephalopathy, mitochondrial disease, multiple sclerosis, Niemann-Pick disease, spinal muscular atrophy and stroke, among others.

Westvac Biopharma Co. Ltd. has described keto amide derivatives acting as 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).

Wuhan Zhongcheng Health Bio-Pharm Technology Co. Ltd. has divulged naphthyridine derivatives acting as ATR kinase inhibitors reported to be useful for the treatment of cancer, psoriasis, keloids and benign prostatic hyperplasia.

Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has identified mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer.